MAR 18, 2013
ThromboGenics announced a net profit of 30.4 million euros for 2012, compared to a net loss of 21.6 million euros in 2011. Total revenue for the year was 75.1 million euros, compared with 2.5 million euros in 2011.
The Brussels-based company highlighted a number of factors for the turnaround, including the FDA approval of Jetrea (ocriplamsmin) for symptomatic macular adhesion, a 375 million-euro agreement with Alcon for the commercialization of Jetrea outside the U.S., as well as raising 77.9 million euros via a private placement.
"The past 12 months have been the most important period in ThromboGenics' history," CEO Dr. Patrik De Haes said. "The recent launch of Jetrea has completed our transformation into a profitable fully integrated company focused on developing and commercializing innovative ophthalmic medicines."
Jetrea was launched in the U.S. in January and received European approval this week.